VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CNTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CNTXContext Therapeutics Inc.
$0.17$16M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
CNTX logo

Context Therapeutics Inc.

CNTX
NASDAQ · Oncology Biotech
$0.17
At close - Nov 16, 4:00 PM EST - USD
Market Cap$15M
P/E-0.4x
52W High$3.62
Volume2.87M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Clinical Development Costs Drive Persistent Equity Erosion

Context Therapeutics remains a high-risk, clinical-stage biotechnology firm whose valuation is entirely tethered to the successful advancement of its ONA-XR and CLDN6 programs.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

CNTX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 3 · Lag

Laggard (Underperforming 97% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 10

Market performance

Price History →

Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
CNTX-89.30%
S&P 500 (^GSPC)+8.31%
1-Year Return
CNTX-85.57%
S&P 500 (^GSPC)+11.16%
3-Year Return
CNTX-83.57%
S&P 500 (^GSPC)+60.75%
5-Year Return
CNTX-96.61%
S&P 500 (^GSPC)+55.88%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$36M-35.2% YoY
Free cash flow FY25
-$26M+9.9% YoY
Operating margin FY25
-
ROIC (FY25)-
Avg ROIC 5Y-
ROE (TTM)-96.5%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (42%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 10, 2026
-$0.08+25.6%
vs -$0.11
—
vs —
Q3 2026
Aug 5, 2026
-$0.15-62.8%
vs -$0.09
—
vs —
Q2 2026
May 6, 2026
-$0.09+25.0%
vs -$0.12
—
vs —
Q2 2026
Mar 19, 2026
-$0.14-27.3%
vs -$0.11
—
vs $1M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Nov 10, 2026
Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress

CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR,  56% confirmed DCR, and median PFS of 5.6 months

Zacks Investment Research·Oct 15, 2026
New Strong Sell Stocks for October 15th

CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.

Zacks Investment Research·Oct 13, 2026
New Strong Sell Stocks for October 13th

ATS, CANG and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2026.

GlobeNewsWire·Sep 9, 2026
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 TCE bispecific antibody.

Filtered for Context Therapeutics Inc.More Headlines
04

Compare before deciding

Benchmark CNTX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Context Therapeutics Inc. (CNTX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CNTX logoCNTXContext Therapeutics Inc.Current
$0.17$15.24M-0.36——-96.54%—
AGEN logoAGENAgenus Inc.
$6.29$261.93M18.6410.37%20.98%——
IMVT logoIMVTImmunovant, Inc.
$33.28$6.87B-13.51—-7173.52%-63.01%—
ONCO logoONCOOnconetix, Inc.
$2.91$1.04M-0.06-67.7%-1578.79%-91.95%—
TPVG logoTPVGTriplePoint Venture Growth BDC Corp.
$3.78$153.46M7.0655.25%58.87%6.24%27.11%
AGIO logoAGIOAgios Pharmaceuticals, Inc.
$30.15$1.79B-4.8348.03%-264.76%-34.63%—

Compare CNTX vs Peers

Context Therapeutics Inc. (CNTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs AGEN

Most directly comparable listed peer for CNTX.

Scale Benchmark

vs IQV

Larger-name benchmark to compare CNTX against a more recognizable public peer.

Peer Set

Compare Top 5

vs AGEN, IMVT, ONCO, TPVG

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

CNTX SEC Filings & Documents

Context Therapeutics Inc. (CNTX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 10, 2026·SEC

Material company update

Aug 5, 2026·SEC

Material company update

Jul 31, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 23, 2026·SEC

FY 2025

Mar 20, 2025·SEC

FY 2024

Mar 21, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 10, 2026·SEC

FY 2026

Aug 5, 2026·SEC

FY 2026

May 6, 2026·SEC

Get notified when CNTX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CNTX Frequently Asked Questions

Context Therapeutics Inc. (CNTX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is CNTX profitable?

No. Context Therapeutics Inc. (CNTX) reported a net loss of $43.9M over the trailing twelve months.

Dividend & Returns
What is CNTX's return on equity?

Context Therapeutics Inc. (CNTX) had a return on equity (ROE) of -96.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Context Therapeutics Inc.'s free cash flow?

Context Therapeutics Inc. (CNTX) had negative free cash flow of $34.0M over the trailing twelve months.

What if you invested $1,000 in CNTX back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →